IDEAS home Printed from https://ideas.repec.org/a/eee/socmed/v292y2022ics0277953621009084.html
   My bibliography  Save this article

Healthcare policy by other means: Cancer clinical research as “oncopolicy”

Author

Listed:
  • Cambrosio, Alberto
  • Campbell, Jonah
  • Keating, Peter
  • Polk, Jessica B.
  • Aguilar-Mahecha, Adriana
  • Basik, Mark

Abstract

Social studies of biomedicine often focus on how exogenous policies shape the medical domain. While policy agendas no doubt affect complex biomedical projects, in the present paper we analyze a different dynamic, namely how oncologists enact policy as part of several flagship precision oncology endeavors. Empirically, the article focuses on the U.S. TAPUR trial, the Dutch DRUP trial, and the Canadian CAPTUR trial, which have recently been joined by similar Scandinavian studies. Taken together, these trials represent innovative forms of clinical research that, beyond their varying experimental nature, have been designed to transform the evidential processes to provide access to biomarker-driven treatments. Along with gathering evidence on effectiveness of off-label targeted therapies, their explicit goals include the recentering of a major professional organization around research, and the reframing of healthcare as a learning system seamlessly connecting epistemic, organizational, and economic issues. Accordingly, we analyze the design and implementation of these trials as a form of (onco)policy by other means.

Suggested Citation

  • Cambrosio, Alberto & Campbell, Jonah & Keating, Peter & Polk, Jessica B. & Aguilar-Mahecha, Adriana & Basik, Mark, 2022. "Healthcare policy by other means: Cancer clinical research as “oncopolicy”," Social Science & Medicine, Elsevier, vol. 292(C).
    • Handle: RePEc:eee:socmed:v:292:y:2022:i:c:s0277953621009084
    DOI: 10.1016/j.socscimed.2021.114576
    as

    Download full text from publisher

    File URL: http://www.sciencedirect.com/science/article/pii/S0277953621009084
    Download Restriction: Full text for ScienceDirect subscribers only
    File URL: https://libkey.io/10.1016/j.socscimed.2021.114576?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. D. L. Velden & L. R. Hoes & H. Wijngaart & J. M. Berge Henegouwen & E. Werkhoven & P. Roepman & R. L. Schilsky & W. W. J. Leng & A. D. R. Huitema & B. Nuijen & P. M. Nederlof & C. M. L. Herpen & D. J., 2019. "The Drug Rediscovery protocol facilitates the expanded use of existing anticancer drugs," Nature, Nature, vol. 574(7776), pages 127-131, October.
    2. Hogarth, Stuart, 2015. "Neoliberal technocracy: Explaining how and why the US Food and Drug Administration has championed pharmacogenomics," Social Science & Medicine, Elsevier, vol. 131(C), pages 255-262.
    3. Peter Priestley & Jonathan Baber & Martijn P. Lolkema & Neeltje Steeghs & Ewart Bruijn & Charles Shale & Korneel Duyvesteyn & Susan Haidari & Arne Hoeck & Wendy Onstenk & Paul Roepman & Mircea Voda & , 2019. "Pan-cancer whole-genome analyses of metastatic solid tumours," Nature, Nature, vol. 575(7781), pages 210-216, November.
    4. Baszanger, Isabelle, 2012. "One more chemo or one too many? Defining the limits of treatment and innovation in medical oncology," Social Science & Medicine, Elsevier, vol. 75(5), pages 864-872.
    5. Nelson, Nicole C. & Keating, Peter & Cambrosio, Alberto & Aguilar-Mahecha, Adriana & Basik, Mark, 2014. "Testing devices or experimental systems? Cancer clinical trials take the genomic turn," Social Science & Medicine, Elsevier, vol. 111(C), pages 74-83.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Denis Horgan & Bettina Borisch & Ivana Cattaneo & Mark Caulfield & Arturo Chiti & Christine Chomienne & Amanda Cole & Karen Facey & Allan Hackshaw & Minna Hendolin & Nadia Georges & Dipak Kalra & Biru, 2022. "Factors Affecting Citizen Trust and Public Engagement Relating to the Generation and Use of Real-World Evidence in Healthcare," IJERPH, MDPI, vol. 19(3), pages 1-18, February.
    2. Marta Palafox & Laia Monserrat & Meritxell Bellet & Guillermo Villacampa & Abel Gonzalez-Perez & Mafalda Oliveira & Fara Brasó-Maristany & Nusaibah Ibrahimi & Srinivasaraghavan Kannan & Leonardo Mina , 2022. "High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer," Nature Communications, Nature, vol. 13(1), pages 1-20, December.
    3. Oriol Pich & Iker Reyes-Salazar & Abel Gonzalez-Perez & Nuria Lopez-Bigas, 2022. "Discovering the drivers of clonal hematopoiesis," Nature Communications, Nature, vol. 13(1), pages 1-12, December.
    4. Eline J. M. Bertrums & Jurrian K. Kanter & Lucca L. M. Derks & Mark Verheul & Laurianne Trabut & Markus J. Roosmalen & Henrik Hasle & Evangelia Antoniou & Dirk Reinhardt & Michael N. Dworzak & Nora Mü, 2024. "Selective pressures of platinum compounds shape the evolution of therapy-related myeloid neoplasms," Nature Communications, Nature, vol. 15(1), pages 1-16, December.
    5. Lino Möhrmann & Maximilian Werner & Małgorzata Oleś & Andreas Mock & Sebastian Uhrig & Arne Jahn & Simon Kreutzfeldt & Martina Fröhlich & Barbara Hutter & Nagarajan Paramasivam & Daniela Richter & Kat, 2022. "Comprehensive genomic and epigenomic analysis in cancer of unknown primary guides molecularly-informed therapies despite heterogeneity," Nature Communications, Nature, vol. 13(1), pages 1-15, December.
    6. Stuart Hogarth & Paul Martin, 2021. "The ratio of vision to data: Promoting emergent science and technologies through promissory regulation, the case of the FDA and personalised medicine," Regulation & Governance, John Wiley & Sons, vol. 15(3), pages 969-986, July.
    7. Roberta Esposito & Andrés Lanzós & Tina Uroda & Sunandini Ramnarayanan & Isabel Büchi & Taisia Polidori & Hugo Guillen-Ramirez & Ante Mihaljevic & Bernard Mefi Merlin & Lia Mela & Eugenio Zoni & Lusin, 2023. "Tumour mutations in long noncoding RNAs enhance cell fitness," Nature Communications, Nature, vol. 14(1), pages 1-21, December.
    8. Maud Rijnders & J. Alberto Nakauma-González & Debbie G. J. Robbrecht & Alberto Gil-Jimenez & Hayri E. Balcioglu & Astrid A. M. Oostvogels & Maureen J. B. Aarts & Joost L. Boormans & Paul Hamberg & Mic, 2024. "Gene-expression-based T-Cell-to-Stroma Enrichment (TSE) score predicts response to immune checkpoint inhibitors in urothelial cancer," Nature Communications, Nature, vol. 15(1), pages 1-13, December.
    9. Erik Elias & Arman Ardalan & Markus Lindberg & Susanne E. Reinsbach & Andreas Muth & Ola Nilsson & Yvonne Arvidsson & Erik Larsson, 2021. "Independent somatic evolution underlies clustered neuroendocrine tumors in the human small intestine," Nature Communications, Nature, vol. 12(1), pages 1-8, December.
    10. Luan Nguyen & Arne Hoeck & Edwin Cuppen, 2022. "Machine learning-based tissue of origin classification for cancer of unknown primary diagnostics using genome-wide mutation features," Nature Communications, Nature, vol. 13(1), pages 1-12, December.
    11. Tas ML & Van Noesel MM & Van den Boogaard ML & Schild GG & Hehir-Kwa JY & Molenaar JJ & Van Noesel MM & Van de Sande MAJ & Van de Sande MAJ & Bovée JVMG & Flucke UE & Flucke UE & Koster J, 2020. "ZFP42: A New Tumor Predisposition Gene? Presentation of a Patient with two Neoplasms in Childhood," Biomedical Journal of Scientific & Technical Research, Biomedical Research Network+, LLC, vol. 27(5), pages 21166-21172, May.
    12. Anouk C. Jong & Alexandra Danyi & Job Riet & Ronald Wit & Martin Sjöström & Felix Feng & Jeroen Ridder & Martijn P. Lolkema, 2023. "Predicting response to enzalutamide and abiraterone in metastatic prostate cancer using whole-omics machine learning," Nature Communications, Nature, vol. 14(1), pages 1-19, December.
    13. Ozvan Bocher & Cristen J. Willer & Eleftheria Zeggini, 2023. "Unravelling the genetic architecture of human complex traits through whole genome sequencing," Nature Communications, Nature, vol. 14(1), pages 1-4, December.
    14. Hauge, Amalie M., 2020. "One last round of chemo? Insights from conversations between oncologists and lung cancer patients about prognosis and treatment decisions," Social Science & Medicine, Elsevier, vol. 266(C).
    15. Nikki L. Burdett & Madelynne O. Willis & Ahwan Pandey & Laura Twomey & Sara Alaei & David D. L. Bowtell & Elizabeth L. Christie, 2024. "Timing of whole genome duplication is associated with tumor-specific MHC-II depletion in serous ovarian cancer," Nature Communications, Nature, vol. 15(1), pages 1-13, December.
    16. Swallow, Julia & Kerr, Anne & Chekar, Choon Key & Cunningham-Burley, Sarah, 2020. "Accomplishing an adaptive clinical trial for cancer: Valuation practices and care work across the laboratory and the clinic," Social Science & Medicine, Elsevier, vol. 252(C).
    17. Zhe Jiang & YoungJun Ju & Amjad Ali & Philip E. D. Chung & Patryk Skowron & Dong-Yu Wang & Mariusz Shrestha & Huiqin Li & Jeff C. Liu & Ioulia Vorobieva & Ronak Ghanbari-Azarnier & Ethel Mwewa & Maria, 2023. "Distinct shared and compartment-enriched oncogenic networks drive primary versus metastatic breast cancer," Nature Communications, Nature, vol. 14(1), pages 1-22, December.
    18. Xiaojing Wang & Anne-Marie Langevin & Peter J. Houghton & Siyuan Zheng, 2022. "Genomic disparities between cancers in adolescent and young adults and in older adults," Nature Communications, Nature, vol. 13(1), pages 1-16, December.
    19. Perla Pucci & Liam C. Lee & Miaojun Han & Jamie D. Matthews & Leila Jahangiri & Michaela Schlederer & Eleanor Manners & Annabel Sorby-Adams & Joshua Kaggie & Ricky M. Trigg & Christopher Steel & Lucy , 2024. "Targeting NRAS via miR-1304-5p or farnesyltransferase inhibition confers sensitivity to ALK inhibitors in ALK-mutant neuroblastoma," Nature Communications, Nature, vol. 15(1), pages 1-19, December.
    20. W. Dean Pontius & Ellen S. Hong & Zachary J. Faber & Jeremy Gray & Craig D. Peacock & Ian Bayles & Katreya Lovrenert & Diana H. Chin & Berkley E. Gryder & Cynthia F. Bartels & Peter C. Scacheri, 2023. "Temporal chromatin accessibility changes define transcriptional states essential for osteosarcoma metastasis," Nature Communications, Nature, vol. 14(1), pages 1-15, December.

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:eee:socmed:v:292:y:2022:i:c:s0277953621009084. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Catherine Liu (email available below). General contact details of provider: http://www.elsevier.com/wps/find/journaldescription.cws_home/315/description#description .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.